Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

141 ARTÍCULOS , VIENDO DEL 121 AL 135

Potential of functional MRI as a biomarker in early Alzheimer's disease

Sperling R.

Neurobiol Aging. 2011 Dec;32 Suppl 1(Suppl 1):S37-43. doi: 10.1016/j.neurobiolaging.2011.09.009.

Alliance for aging research AD biomarkers work group: structural MRI

Jack CR Jr.

Neurobiol Aging. 2011 Dec;32 Suppl 1(0 1):S48-57. doi: 10.1016/j.neurobiolaging.2011.09.011.

Changes in cognition

Albert MS.

Neurobiol Aging. 2011 Dec;32 Suppl 1(0 1):S58-63. doi: 10.1016/j.neurobiolaging.2011.09.010.

Obesity, leptin, and Alzheimer's disease

Lee EB.

Ann N Y Acad Sci. 2011 Dec;1243:15-29. doi: 10.1111/j.1749-6632.2011.06274.x.

Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets

Lee VM, Brunden KR, Hutton M, Trojanowski JQ.

Cold Spring Harb Perspect Med. 2011 Sep;1(1):a006437. doi: 10.1101/cshperspect.a006437.

C-peptide and its correlation to parameters of insulin resistance in the metabolic syndrome

Banu S, Jabir NR, Manjunath CN, Shakil S, Kamal MA.

CNS Neurol Disord Drug Targets. 2011 Dec;10(8):921-7. doi: 10.2174/187152711799219271.

Granular expression of prolyl-peptidyl isomerase PIN1 is a constant and specific feature of Alzheimer's disease pathology and is independent of tau, Aβ and TDP-43 pathology

Dakson A, Yokota O, Esiri M, Bigio EH, Horan M, Pendleton N, Richardson A, Neary D, Snowden JS, Robinson A, Davidson YS, Mann DM.

Acta Neuropathol. 2011 May;121(5):635-49. doi: 10.1007/s00401-011-0798-y. Epub 2011 Jan 18.

Developing predictive CSF biomarkers-a challenge critical to success in Alzheimer's disease and neuropsychiatric translational medicine

Flood DG, Marek GJ, Williams M.

Biochem Pharmacol. 2011 Jun 15;81(12):1422-34. doi: 10.1016/j.bcp.2011.01.021. Epub 2011 Feb 3.

Developing predictive biomarkers for dementia of Parkinson's disease

Caviness JN, Aarsland D.

Expert Rev Neurother. 2011 Dec;11(12):1661-3. doi: 10.1586/ern.11.159.

α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study

Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Döring F, Trenkwalder C, Schlossmacher MG.

Lancet Neurol. 2011 Mar;10(3):230-40. doi: 10.1016/S1474-4422(11)70014-X.

Peripheral expression of key regulatory kinases in Alzheimer's disease and Parkinson's disease

Armentero MT, Sinforiani E, Ghezzi C, Bazzini E, Levandis G, Ambrosi G, Zangaglia R, Pacchetti C, Cereda C, Cova E, Basso E, Celi D, Martignoni E, Nappi G, Blandini F.

Neurobiol Aging. 2011 Dec;32(12):2142-51. doi: 10.1016/j.neurobiolaging.2010.01.004. Epub 2010 Jan 27.

Differential levels of apolipoprotein E and butyrylcholinesterase show strong association with pathological signs of Alzheimer's disease in the brain in vivo

Darreh-Shori T, Forsberg A, Modiri N, Andreasen N, Blennow K, Kamil C, Ahmed H, Almkvist O, Långström B, Nordberg A.

Neurobiol Aging. 2011 Dec;32(12):2320.e15-32. doi: 10.1016/j.neurobiolaging.2010.04.028. Epub 2010 Jun 9.

Prediction of MCI to AD conversion, via MRI, CSF biomarkers, and pattern classification

Davatzikos C, Bhatt P, Shaw LM, Batmanghelich KN, Trojanowski JQ.

Neurobiol Aging. 2011 Dec;32(12):2322.e19-27. doi: 10.1016/j.neurobiolaging.2010.05.023. Epub 2010 Jul 1.

Cerebrospinal fluid profile of amyloid β42 (Aβ42), hTau and ubiquitin in North Indian Alzheimer's disease patients

Kandimalla RJ, S P, Bk B, Wani WY, Sharma DR, Grover VK, Bhardwaj N, Jain K, Gill KD.

Neurosci Lett. 2011 Jan 7;487(2):134-8. doi: 10.1016/j.neulet.2010.06.075. Epub 2010 Jul 3.

[Diagnosis contribution of biomarkers in Alzheimer disease: A case of frontotemporal dementia]

Richard-Mornas A, Dirson S, Perret-Liaudet A, Decousus M, Thomas-Antérion C.

Rev Neurol (Paris). 2011 Feb;167(2):160-3. doi: 10.1016/j.neurol.2010.06.003. Epub 2010 Jul 31.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias